Abstract: An actuation system includes: a generating rotating electrical machine including a first stator including at least one output stator winding; a driving rotating electrical machine including a second rotor, intended to actuate a lubrication pump, and a second stator including at least one input stator winding; an array of switches electrically connected to the at least one output stator winding and to the at least one input stator winding, for electrically connecting them together or disconnecting them from each other depending on the state of the array of switches; and a control device configured to control the array of switches, depending on the state of a control signal, in such a way as to electrically connect or not connect the at least one output stator winding and the at least one input stator winding together.

Abstract: In an electromechanical actuation chain for controlling the movement of mobile loads of an aircraft turbine engine, from a control unit, one or more of these mobile loads being actuated by an electromechanical actuator, there is provided for control of this movement a single Ethernet controller having deterministic control that uses an Ethernet bus to control a set of converters acting selectively on the electromechanical actuators.

Abstract: A power distribution device between an electric starter of a turbomachine and an electric machine toward a shaft of the turbomachine, including the electric starter, the electric machine, and a controller for controlling the electric machine. An epicyclic train reducer includes a first element intended to be coupled to the shaft, a second element coupled to the electric starter, and a third element intended to be rotated by the electric machine. The controller is configured to rotate the third of the three elements so as to obtain two bearings of reduction ratios of the speeds between the first of said three elements and the second of the three elements. The controller is configured to drive the torque of the third of the three elements in accordance with a determined output torque.

Abstract: The invention concerns a bypass turbomachine (1) with a primary flow path and a secondary flow path, comprising: —a low-pressure body comprising a low-pressure compressor (120) connected to a low-pressure turbine (122) via a low-pressure shaft (124), —a high-pressure body comprising a high-pressure compressor (130) connected to a high pressure turbine (132), via a high-pressure shaft (134), —a low-pressure power take-off system (220) comprising an electrical generator (226), configured to take power (W12) from the low-pressure body, wherein—the turbomachine comprises a debris removal system (500), located between the two compressors (226, 236), —the low-pressure power take-off system (220) is configured to take power (W12) from the low-pressure shaft (124) using the resistive torque of the electrical generator (226), in order to avoid a risk of surging.

Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.

Abstract: Provided herein are vaccine combinations and methods for enhancing an antigen specific T cell induced response in a subject in need thereof. The methods combine systemic vaccination with a first composition containing a non-replicating viral vector encoding an antigen or immunogen containing one or more CD8+ T cell epitopes; and/or a second composition with micelles containing fluorocarbon-linked peptides, wherein each peptide linked to the fluorocarbon is: i) 15 to 75 amino acid residues long; ii) from the antigen or immunogen of the first composition; and, iii) contains one or more of the CD8+ T cell epitopes of the first composition from the antigen or immunogen to induce antigen specific CD8+ T cells; and optionally a third composition comprising an immune modulator composition.

Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.

Abstract: A power distribution device between an electric starter of a turbomachine and an electric machine toward a shaft of the turbomachine, including the electric starter, the electric machine, and a controller for controlling the electric machine. An epicyclic train reducer includes a first element intended to be coupled to the shaft, a second element coupled to the electric starter, and a third element intended to be rotated by the electric machine. The controller is configured to rotate the third of the three elements so as to obtain two bearings of reduction ratios of the speeds between the first of said three elements and the second of the three elements. The controller is configured to drive the torque of the third of the three elements in accordance with a determined output torque.

Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.

Abstract: Provided in the present disclosure are immunotherapy compounds, pharmaceutical compositions thereof and their use, wherein the immunotherapy compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.

Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.

Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.

Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.

Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.

Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.

Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.

Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.

Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.

Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.

Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.